Literature DB >> 3416905

The permanent effect of reproductive events on blood prolactin levels and its relation to breast cancer risk: a population study of postmenopausal women.

D Y Wang1, B L de Stavola, R D Bulbrook, D S Allen, H G Kwa, A A Verstraeten, J W Moore, I S Fentiman, J L Hayward, I H Gravelle.   

Abstract

In each of two population-based studies conducted on the Island of Guernsey between 1967-1976 and 1977-1984, respectively, single specimens of blood were taken from over 5000 normal women. From these two studies there were 1173 and 946 postmenopausal women in whom blood prolactin was determined and multivariate analysis was used to establish the association between blood prolactin concentration and possible determinants of risk of breast cancer. Since prolactin levels were log-normally distributed these analyses were done on log-transformed data. The age at menarche or menopause, age at first or last childbirth, length of reproductive life (i.e. time from menarche to menopause) or post-menopausal life (i.e. time from menopause to time of blood sampling), contraceptive use and history of breast cancer were not significantly associated with blood prolactin concentration. Of significance were age, parity, time of blood sampling and assay drift. Ponderosity (Quetelet's Index) was positively associated with prolactin concentration and this was significant using a one-tail criterion. Women with a mammographic pattern designated DY by Wolfe had significantly higher prolactin levels than those with N1 patterns. However, the main finding to emerge was that after standardizing for all the other variables increasing parity was related to a step-wise reduction in blood prolactin levels. Since this had occurred in women who had had their last child up to 35 years previously it implies this effect is permanent. It could therefore be that the protective effect on breast cancer risk of multiparity and early first pregnancy could be mediated by such a life-long reduction in blood prolactin levels.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3416905     DOI: 10.1016/0277-5379(88)90132-0

Source DB:  PubMed          Journal:  Eur J Cancer Clin Oncol        ISSN: 0277-5379


  24 in total

Review 1.  Mammographic densities as a marker of human breast cancer risk and their use in chemoprevention.

Authors:  N F Boyd; L J Martin; J Stone; C Greenberg; S Minkin; M J Yaffe
Journal:  Curr Oncol Rep       Date:  2001-07       Impact factor: 5.075

2.  Determinants of prolactin in postmenopausal Chinese women in Singapore.

Authors:  Tiffany A Katz; Anna H Wu; Frank Z Stanczyk; Renwei Wang; Woon-Puay Koh; Jian-Min Yuan; Steffi Oesterreich; Lesley M Butler
Journal:  Cancer Causes Control       Date:  2017-11-09       Impact factor: 2.506

3.  Reproductive factors and family history of breast cancer in relation to plasma estrogen and prolactin levels in postmenopausal women in the Nurses' Health Study (United States).

Authors:  S E Hankinson; G A Colditz; D J Hunter; J E Manson; W C Willett; M J Stampfer; C Longcope; F E Speizer
Journal:  Cancer Causes Control       Date:  1995-05       Impact factor: 2.506

Review 4.  Epidemiology of endocrine-related risk factors for breast cancer.

Authors:  Leslie Bernstein
Journal:  J Mammary Gland Biol Neoplasia       Date:  2002-01       Impact factor: 2.673

5.  Energy balance, early life body size, and plasma prolactin levels in postmenopausal women.

Authors:  Xuefen Su; Susan E Hankinson; Charles V Clevenger; A Heather Eliassen; Shelley S Tworoger
Journal:  Cancer Causes Control       Date:  2008-10-14       Impact factor: 2.506

6.  Prolactin serum levels and breast cancer: relationships with risk factors and tumour characteristics among pre- and postmenopausal women in a population-based case-control study from Poland.

Authors:  J M Faupel-Badger; M E Sherman; M Garcia-Closas; M M Gaudet; R T Falk; A Andaya; R M Pfeiffer; X R Yang; J Lissowska; L A Brinton; B Peplonska; B K Vonderhaar; J D Figueroa
Journal:  Br J Cancer       Date:  2010-08-24       Impact factor: 7.640

7.  Bioactive prolactin levels and risk of breast cancer: a nested case-control study.

Authors:  Shelley S Tworoger; Megan S Rice; Bernard A Rosner; Yvonne B Feeney; Charles V Clevenger; Susan E Hankinson
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2014-10-14       Impact factor: 4.254

8.  Circulating prolactin levels and risk of epithelial ovarian cancer.

Authors:  Tess V Clendenen; Alan A Arslan; Anna E Lokshin; Mengling Liu; Eva Lundin; Karen L Koenig; Franco Berrino; Goran Hallmans; Annika Idahl; Vittorio Krogh; Annekatrin Lukanova; Adele Marrangoni; Paola Muti; Brian M Nolen; Nina Ohlson; Roy E Shore; Sabina Sieri; Anne Zeleniuch-Jacquotte
Journal:  Cancer Causes Control       Date:  2013-02-03       Impact factor: 2.506

9.  The association of height, weight, menstrual and reproductive events with breast cancer: results from two prospective studies on the island of Guernsey (United Kingdom).

Authors:  B L De Stavola; D Y Wang; D S Allen; J Giaconi; I S Fentiman; M J Reed; R D Bulbrook; J L Hayward
Journal:  Cancer Causes Control       Date:  1993-07       Impact factor: 2.506

10.  Serum hormone levels in British and rural Chinese females.

Authors:  D Y Wang; T J Key; M C Pike; J Boreham; J Chen
Journal:  Breast Cancer Res Treat       Date:  1991-05       Impact factor: 4.872

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.